Nicholas Investment Partners’s Chinook Therapeutics, Inc. Common Stock KDNY Stock Holding History

Nicholas Investment Partners’s Portfolio KDNY Stock Details KDNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-928,637	Closed	-$35.7M	–	212
2023 Q2	$35.7M	Sell	928,637 -43,554	-4%	-$1.12M	2.44%	7
2023 Q1	$22.5M	Buy	972,191 +329,471	+51%	+$7.85M	1.71%	17
2022 Q4	$16.8M	Buy	642,720 +75,305	+13%	+$1.67M	1.48%	17
2022 Q3	$11.2M	Buy	567,415 +17,561	+3%	+$352K	1.03%	36
2022 Q2	$9.62M	Buy	549,854 +410,036	+293%	+$6.44M	0.91%	37
2022 Q1	$2.29M	Buy	+139,818	New	+$1.9M	0.16%	140

Nicholas Investment Partners's KDNY Position: Q3 2023 in Review

Nicholas Investment Partners sold out of Chinook Therapeutics, Inc. Common Stock (KDNY) in Q3 2023, closing a stake of 928,637 shares — an estimated $35.7M sold.

Nicholas Investment Partners first reported a position in KDNY in Q1 2022 and held it in 6 quarters. The position peaked at $35.7M in Q2 2023. 2 funds tracked by Wall St. Rank hold KDNY as of Q3 2023.

Nicholas Investment Partners reported no remaining Chinook Therapeutics, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
Nicholas Investment Partners sold 928,637 Chinook Therapeutics, Inc. Common Stock shares in Q3 2023, an estimated $35.7M.
Nicholas Investment Partners first reported a position in Chinook Therapeutics, Inc. Common Stock in Q1 2022 and held it in 6 quarters.
Nicholas Investment Partners's Chinook Therapeutics, Inc. Common Stock position peaked at $35.7M in Q2 2023.
2 funds tracked by Wall St. Rank held Chinook Therapeutics, Inc. Common Stock as of Q3 2023.

Based on Nicholas Investment Partners's 13F filing for Q3 2023, filed 13 Nov 2023.